Lumida
/LENZ
⌘K
LENZ Therapeutics Inc

LENZ Therapeutics Inc

LENZ
$4.52USD-4.24%-0.20 today

MARKET CAP

142.0M

P/E (TTM)

FWD P/E

DAY RANGE

$5 – $5

52W RANGE

$5
$50

AI Summary

Stalk
TrimMedium

LENZ is in a Stage 4 decline with persistent lower highs and lower lows under down-sloping EMAs, confirming bearish structure across both medium and long terms. Short-term execution timing is neutral as price tightly tracks below declining EMAs amid extreme oversold readings, offering no clear entry. With a speculative strategy requiring high selectivity, execution is deferred and best considered on any rally into EMA resistance.

  • Moderate Buy consensus with $28.80 price target implies ~509% upside.
  • VIZZ prescriptions surged 45% month-over-month after marketing push.
  • Q2 2026 net loss of $31.9M despite VIZZ revenue growth.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2025TREND
Sales, Adj.$19.1M
YoY %
P / Sales24.2x
EV / Sales24.0x
Gross Profit, Adj.$18.7M
YoY %
Margin %97.8%
EV / Gross Profit24.5x
EBITDA, Adj.$-90.9M
YoY %-55.2%
Margin %-476.0%
EV / EBITDA-5.0x
EBIT$-91.1M
YoY %-55.5%
Margin %-477.5%
EV / EBIT-5.0x
Net Income$-82.1M
YoY %-65.6%
Net Margin-430.0%
EPS (GAAP)-$2.85
YoY %-21.8%